Contradictions Unveiled: Navigating Regulatory Challenges and Clinical Data for RGX-121 in 2025

None



Strong Clinical and Business Progress:
- REGENXBIO reported significant progress in its late-stage clinical trials, with the expectation of multiple first or best-in-class gene therapies over the next few years.
- The progress is driven by the success of RGX-121 for MPS II and RGX-202 for Duchenne muscular dystrophy, which are in advanced stages of development.

RGX-121 and RGX-202 Pivotal Studies:
- The pivotal phase of the AFFINITY DUCHENNE trial for RGX-202 surpassed 50% enrollment, with a high interest from the Duchenne community.
- The rapid enrollment and positive outcomes are due to the differentiated profile and potential benefits of RGX-202 compared to current treatments.

Manufacturing Capabilities and Commercial Readiness:
- REGENXBIO plans to begin commercial supply manufacturing for RGX-202 in the third quarter of 2025, aiming for a 2027 commercial launch.
- The decision is based on strong enrollment in the pivotal study and the capacity of the Manufacturing Innovation Center to produce up to 2,500 doses per year.

Financial Position and Non-dilutive Funding:
- The company ended the quarter with $272 million in cash, cash equivalents, and marketable securities, driven by a $110 million upfront payment from Nippon Shinyaku.
- REGENXBIO's financial strength is supported by non-dilutive financing options that could extend its cash runway beyond 2026, including development and sales milestones.